Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Étude contre le diabète de type 2 intratable (CAPTAIN-T2D) (CAPTAIN-T2D)

5 octobre 2026 mis à jour par: Sparrow Pharmaceuticals

Essai de Phase 2 du Clofutribène et du Placebo contre le Diabète de Type 2 Intratable (CAPTAIN-T2D)

CAPTAIN-T2D will take place in two parts. Part 1 (Screening) will evaluate patients with type 2 diabetes and elevated cortisol risk factors for trial eligibility and the presence of elevated cortisol. Participants deemed eligible from Part 1 will be randomized to either clofutriben or placebo in the double-blind (participant and investigator), dose-ranging, interventional Part 2 (Treatment).

Aperçu de l'étude

Statut

Recrutement

Description détaillée

CAPTAIN-T2D is a two-part, multicenter, randomized, double-blind, parallel group, placebo- controlled trial of the 11-hydroxysteroid dehydrogenase type 1 (HSD-1) inhibitor clofutriben. The primary objectives of this trial are to characterize the relationship of clofutriben dose to improved glycemic control, and to identify one or more doses suitable for Phase 3 evaluation, in patients with T2D and elevated cortisol.

The trial consists of two parts.

Part 1 (Screening) will last between approximately 5 to 9 weeks for most participants. The screening period duration allows for (sequentially) initial eligibility screen, dexamethasone suppression test, and further eligibility assessments.

During Part 2 (Treatment), participants will be randomized to placebo or one of four clofutriben doses. Part 2 will last 24 weeks with a follow-up phone call 4 weeks after the last dose of trial medication.

Type d'étude

Interventionnel

Inscription (Estimé)

1500

Phase

  • Phase 2

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

    • Arizona
      • Chandler, Arizona, États-Unis, 85225
        • Recrutement
        • Arizona Clinical Trials - Pecos
        • Contact:
      • Tucson, Arizona, États-Unis, 85711
    • California
      • Fountain Valley, California, États-Unis, 92708
        • Recrutement
        • Ark Clinical Research - Fountain Valley
        • Contact:
      • Huntington Park, California, États-Unis, 90255
        • Recrutement
        • Velocity Clinical Research, Huntington Park
        • Contact:
      • La Mesa, California, États-Unis, 91942
      • Long Beach, California, États-Unis, 90815
      • Los Angeles, California, États-Unis, 90057
      • Los Angeles, California, États-Unis, 90015
        • Recrutement
        • Los Angeles Institute for Metabolic Research
        • Contact:
      • Northridge, California, États-Unis, 98433
        • Recrutement
        • Amicis Research Center- Nordhoff
        • Contact:
      • San Diego, California, États-Unis, 92120
    • Florida
      • Edgewater, Florida, États-Unis, 32132
        • Recrutement
        • Velocity Clinical Research, New Smyrna Beach
        • Contact:
      • Fort Lauderdale, Florida, États-Unis, 33312
        • Recrutement
        • The Center for Diabetes and Endocrine Care
        • Contact:
      • Miami, Florida, États-Unis, 33173
      • New Port Richey, Florida, États-Unis, 34652
      • Port Charlotte, Florida, États-Unis, 33952
        • Recrutement
        • Innovative Research Institute
        • Contact:
      • Port Orange, Florida, États-Unis, 32127
      • Winter Park, Florida, États-Unis, 32789
    • Georgia
      • Atlanta, Georgia, États-Unis, 30303
        • Recrutement
        • Emory University School of Medicine
        • Contact:
      • Columbus, Georgia, États-Unis, 31904
    • Idaho
      • Boise, Idaho, États-Unis, 83709
    • Illinois
      • Chicago, Illinois, États-Unis, 60607
        • Recrutement
        • Chicago Clinical Research Institute
        • Contact:
          • Manognya Clinical Research Manager
          • Numéro de téléphone: 303 3127913241
          • E-mail: manognya@ccrii.us
    • Iowa
      • West Des Moines, Iowa, États-Unis, 50226
        • Recrutement
        • Iowa Diabetes and Endocrinology Research Center
        • Contact:
    • Kansas
      • Wichita, Kansas, États-Unis, 67226
        • Recrutement
        • Alliance for Multispecialty Research - Wichita East
        • Contact:
    • Kentucky
      • Edgewood, Kentucky, États-Unis, 41017
    • Louisiana
      • Lafayette, Louisiana, États-Unis, 70508
      • Metairie, Louisiana, États-Unis, 70006
        • Recrutement
        • NOLA Care Clinical Research
        • Contact:
      • New Orleans, Louisiana, États-Unis, 70112
        • Recrutement
        • Tulane University School of Medicine
        • Contact:
    • Maryland
      • Rockville, Maryland, États-Unis, 20854
    • Massachusetts
      • Springfield, Massachusetts, États-Unis, 011030
    • Michigan
      • Troy, Michigan, États-Unis, 48085
        • Recrutement
        • Oakland Medical Research Center
        • Contact:
          • Juliejo (Julie) Clinical Research Manager
          • Numéro de téléphone: 248-687-7412
          • E-mail: juliejolafave@msn.com
    • Nebraska
      • Lincoln, Nebraska, États-Unis, 68510
      • Omaha, Nebraska, États-Unis, 68134
    • Nevada
      • Las Vegas, Nevada, États-Unis, 89148
      • Las Vegas, Nevada, États-Unis, 89108
    • New York
      • Albany, New York, États-Unis, 12203
        • Recrutement
        • Albany Medical College
        • Contact:
    • North Carolina
      • Chapel Hill, North Carolina, États-Unis, 27514
        • Recrutement
        • University of North Carolina at Chapel Hill
        • Contact:
      • Greenville, North Carolina, États-Unis, 27834
      • Morehead City, North Carolina, États-Unis, 28557
      • Wilmington, North Carolina, États-Unis, 28401
        • Recrutement
        • PMG Research of Wilmington, LLC
        • Contact:
    • Ohio
      • Cincinnati, Ohio, États-Unis, 45219
        • Recrutement
        • Velocity Clinical Research, Cincinnati, Mt. Auburn
        • Contact:
      • Cincinnati, Ohio, États-Unis, 45242
        • Recrutement
        • Velocity Clinical Research - Cincinnati, Blue Ash
        • Contact:
      • Columbus, Ohio, États-Unis, 43201
        • Recrutement
        • Endocrinology Associates, Inc
        • Contact:
      • Columbus, Ohio, États-Unis, 43215
        • Recrutement
        • Remington Davis, Inc
        • Contact:
          • Tsunami Clinical Research Manager
          • Numéro de téléphone: 614-487-2560
          • E-mail: Tbrisco@remdavis.com
    • Oregon
      • Eugene, Oregon, États-Unis, 97404
        • Recrutement
        • Willamette Valley Clinical Studies
        • Contact:
          • Patricia Manager
          • Numéro de téléphone: 541-461-0132
          • E-mail: drpatb@aol.com
    • Pennsylvania
      • West Chester, Pennsylvania, États-Unis, 19380
    • South Carolina
      • Anderson, South Carolina, États-Unis, 29621
      • Mt. Pleasant, South Carolina, États-Unis, 29464
    • Texas
      • Austin, Texas, États-Unis, 78759
      • Dallas, Texas, États-Unis, 75230
      • Houston, Texas, États-Unis, 77040
      • Lampasas, Texas, États-Unis, 76550
        • Recrutement
        • Radiance Clinical Research
        • Contact:
      • Lewisville, Texas, États-Unis, 75057
        • Recrutement
        • Alliance Clinical - Lewisville (Epic Clinical Research)
        • Contact:
      • Mission, Texas, États-Unis, 78572
        • Recrutement
        • Texas Valley Clinical Research - Mission, TX
        • Contact:
      • Round Rock, Texas, États-Unis, 78681
        • Recrutement
        • Texas Diabetes & Endocrinology, P.A. - Round Rock
        • Contact:
      • San Antonio, Texas, États-Unis, 78229
        • Recrutement
        • Diabetes & Glandular Disease Clinic, P.A.
        • Contact:
      • San Antonio, Texas, États-Unis, 78251
        • Recrutement
        • Texas Valley Clinical Research - San Antonio TX
        • Contact:
      • Seabrook, Texas, États-Unis, 77586
      • Weslaco, Texas, États-Unis, 78596
        • Recrutement
        • Texas Valley Clinical Research, LLC
        • Contact:
    • Utah
      • West Jordan, Utah, États-Unis, 84088
        • Recrutement
        • Velocity Clinical Research, Salt Lake City
        • Contact:
    • Virginia
      • Suffolk, Virginia, États-Unis, 23435
      • Vienna, Virginia, États-Unis, 22182

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • From Screening 1

    • Age at least 18 years.

    • HbA1c ≥7.5% documented within 3 months prior to Screening 1. (The historical HbA1c value must have been obtained after at least 2 months on the current [as of Screening 1] regimen).

    • Treatment with stable and adequate doses of ≥2 injectable or oral ADMs. (An ADM will be deemed stable if the dose has been the same for at least 3 months prior to Screening 1 and without change between Screening 1 and Day 1) (An ADM dose will be deemed adequate if it is at or above the maximal labelled dose, or a sub-maximal, but not starting, dose if limited by tolerability (confer with MM if less than half-maximal dose).

    • Adequate total daily insulin is defined as at least 0.3 units/kg/day. Insulin dose will be deemed stable with adjustments of up to 20% total daily dose during the 3 months prior to Screening 1 or between Screening 1 and Day 1.

    • Use of insulin pumps or insulin brand changes (e.g., due to insurance change or shortage) are to be discussed with the MM.

    • At least one of the following

      • ≥3 stable and adequate ADMs;
      • diabetes complication (retinopathy, nephropathy, neuropathy, atherosclerotic heart disease);
      • hypertension requiring ≥2 adequately dosed AHMs;
      • adequately dosed basal or basal plus prandial insulin in addition to at least 1 other ADM; and
      • adequately dosed incretin agonist (a single or combination agent counts as one ADM) in addition to at least 1 other ADM;
      • evidence or history of osteoporosis or non-traumatic fracture (e.g., vertebral body compression);
      • or established diagnosis of a neoplastic (non-malignant) source of hypercortisolism and have failed, are ineligible for, or declined surgery.

At DST • Post-DST cortisol level >1.8 µg/dL and serum dexamethasone ≥140 ng/dL. Patients with an established diagnosis of neoplastic hypercortisolism do not require a DST.

At Screening 2

  • HbA1c ≥7.5% at Screening 2. At Day 1
  • No change in, or initiation of, medications for hypertension within 1 month prior to Day 1.

Exclusion Criteria:

  • New-onset diabetes (onset <1 year in the past).

  • Unwillingness to maintain with current glucose-lowering regimen during the trial.

  • Unwillingness to adjust, add, replace, or discontinue current or other glucose-lowering medications during the trial as directed by the investigator.

  • Unwillingness to comply with CGM or other trial procedures.

  • Investigator considers the patient will otherwise be unwilling or unable to complete the trial.

  • Night-shift worker or otherwise habitually awake from 23:00 to 07:00 h.

  • Evidence for significant hypoglycemia while on their current diabetic treatment regimen(This includes episodes of symptomatic Level 3 hypoglycemia requiring external assistance for recovery, or CGM-documented prolonged [>15 min] or repeated episodes of either Level 2 hypoglycemia leading to >1%, or Level 1 hypoglycemia leading to >4%, in "time below range" within 3 months prior to Screening 1 or between Screening 1 and Day 1).

  • Any of the following in medical history:

    • Type 1 diabetes mellitus (T1D), latent autoimmune diabetes in adults (LADA), or familial forms of maturity-onset diabetes of the young (MODY);
    • A hemoglobinopathy or other condition which may interfere with measurement of HbA1c (e.g., sickle cell disease HbSS or other variants HbEE thalassemia, hemolytic anemia, recent blood transfusion);
    • Hypersensitivity or severe reaction to dexamethasone;
    • Pheochromocytoma, or suspicion thereof;
    • Anorexia, or other eating disorder;
    • Glucocorticoid resistance;
    • Multiple sclerosis;
    • Significant hepatic impairment (e.g., Child-Pugh Class B or C);
    • Idiopathic thrombocytopenic purpura;
    • Untreated or inadequately controlled moderate-to-severe sleep apnea (apnea-hypopnea index ≥15). (Patients whose condition has been well controlled with Continuous Positive Airway Pressure (CPAP) use for at least 3 months prior to Screening 1 are not excluded. Patients with a STOP-BANG score 5-8 should be referred for a sleep study outside the trial and may rescreen if found not to have moderate-to-severe sleep apnea);
    • Current alcohol consumption >14 units/week or >4 units in a single day for males, or >7 units/week or >3 units in a single day for females. (Patients with a CAGE score 2-4 should be evaluated further outside the trial and may be rescreened if found not to have an alcohol [or other substance] use disorder);
    • Untreated or inadequately controlled major depressive disorder, generalized anxiety disorder, bipolar disorder, post-traumatic stress disorder, or schizophrenia.(Patients whose condition has been well controlled with stable medical therapy, or has been asymptomatic, for at least 3 months prior to Screening 1 are not excluded); or
    • Any other medical condition (including malignancy) that is likely to interfere with trial assessments or the patient's ability to complete the trial.
    • Any of the following in medication history:
    • Any of the excluded medications listed in Section 6.9;
    • Any investigational drug within 4 weeks or within less than five times the drug's half-life, whichever is longer, prior to Screening 1 or between Screening 1 and Day 1;
    • Woman of childbearing potential (WOCBP) not willing to adhere to highly effective contraception or strict abstinence for the duration of the trial and for 90 days post completion/discontinuation; and
    • Pregnancy (including a positive urine test) or current breast feeding.

From Screening 2

• Prior probability of undiagnosed endogenous Cushing syndrome based on either of:

  • wo morning serum cortisol values after dexamethasone suppression >5.0 mcg/dL together with plasma dexamethasone >140 ng/mL; or
  • a morning serum cortisol value after dexamethasone suppression >1.8 mcg/dL, together with plasma dexamethasone >140 ng/mL and any one of the following that is not attributable to an etiology other than endogenous Cushing's syndrome:
  • supraclavicular/dorsocervical fat accumulation;
  • irounding of the face (especially compared with prior photos);
  • skin changes (violaceous striae, skin thinning, or excessive bruising);
  • proximal muscle weakness on exam; or
  • history of deep vein thrombosis/pulmonary embolism.
  • Plans for, or medically unable to forego, treatment for endogenous Cushing syndrome or ACS within the next 8 months. (For clarity, patients with EnCS or ACS, not having such treatment plans, and medically able to forego treatment for 8 months may enroll if otherwise eligible).
  • Severe, poorly controlled hypertension (mean systolic BP >160 mmHg or mean diastolic BP >100 mmHg) at Screening 2 or between Screening 2 and Day 1, including by at-home monitoring. (Such patients will be eligible to rescreen for Part 2 when they restore BP <160/100 mmHg for 1 month on a new stable medication regimen).
  • Positive urine screen for recreational drugs (except tetrahydrocannabinol (THC)).
  • Glomerular filtration rate (GFR) (determined using Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI]) <45 mL/min/1.73 m².
  • Poorly controlled hyperthyroidism/hypothyroidism (confirmed by TSH or Free thyroxine [fT4]).
  • Liver enzymes >3 × upper limit of normal (ULN) (alanine aminotransferase (ALT) or aspartate aminotransferase (AST) or bilirubin >1.5 × ULN.(excepting benign conditions such as Gilbert's)
  • Known hypersensitivity to clofutriben or to any of the product

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Autre
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Quadruple

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Dose 1

clofutriben .2 mg oral tablet daily

HSD-1 inhibitor

Autres noms:
  • SPI-62
  • ASP3662
Expérimental: Dose 2

clofutriben 2mg oral tablet daily

HSD-1 inhibitor

Autres noms:
  • SPI-62
  • ASP3662
Expérimental: Dose 3

clofutriben 6mg oral tablet daily

HSD-1 inhibitor

Autres noms:
  • SPI-62
  • ASP3662
Expérimental: Dose 4

clofutriben 12 mg oral tablet daily

HSD-1 inhibitor

Autres noms:
  • SPI-62
  • ASP3662
Comparateur placebo: placebo

placebo control oral tablet daily

Placebo

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Percentage of patients with both morning serum cortisol >1.8 mg/dL and morning plasma dexamethasone >=140 ng/dL (single composite endpoint) after a single dexamethasone 1 mg dose taken the prior night.
Délai: 8-10 hours after the dexamethasone 1 mg dose.

To assess prevalence in the trial population of morning cortisol non-suppression by a single dexamethasone 1 mg dose.

8-10 hours after the dexamethasone 1 mg dose.
Glycated hemoglobin A1c (%) change from baseline to Week 24 by treatment.
Délai: 24 weeks.

To assess glycated hemoglobin A1c (%) changes, compared to placebo, in patients who receive each of 4 daily clofutriben doses for 24 weeks.

24 weeks.

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Fasting plasma glucose (mmol/L) change from baseline to Week 24 by treatment.
Délai: 24 weeks

To assess glucose (mmol/L) changes, compared to placebo, in patients who receive each of 4 daily clofutriben doses for 24 weeks.

24 weeks

Autres mesures de résultats

Mesure des résultats
Description de la mesure
Délai
To evaluate the safety of clofutriben in participants with T2D and EC.
Délai: From enrollment until end of trial 9 month

Frequency of TEAEs (treatment-emergent adverse even) by clofutriben dose

From enrollment until end of trial 9 month

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

29 novembre 2025

Achèvement primaire (Estimé)

31 décembre 2027

Achèvement de l'étude (Estimé)

30 juin 2028

Dates d'inscription aux études

Première soumission

30 novembre 2025

Première soumission répondant aux critères de contrôle qualité

18 décembre 2025

Première publication (Réel)

22 décembre 2025

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

6 octobre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

5 octobre 2026

Dernière vérification

1 octobre 2026

Plus d'information

Termes liés à cette étude

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Oui

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner